Pascal Soriot

Rule Changes

Led AstraZeneca through the Enhertu development and UK pricing agreement

The National Institute for Health and Care Excellence published final guidance on October 7, confirming that about 1,000 people a year in England can get Enhertu for HER2-low advanced breast cancer. The decision ended a 26-month dispute over price, after the UK raised what it will pay per quality-adjusted life year from £30,000 to £35,000.

Updated Oct 24

Money Moves

Driving AstraZeneca's oncology and ADC combination strategy

AstraZeneca closed its $2 billion Summit Therapeutics investment on October 5: a straight equity purchase with no royalties or milestones attached, according to Biotech Morning. The cash funds trials pairing Summit's ivonescimab, a bispecific antibody that blocks PD-1 and VEGF, with AstraZeneca's antibody-drug conjugates.

Updated Oct 21